China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Simcere securing Greater China rights to RB0026, Immunofoco resubmitting its Hong Kong IPO, Fulcrum merging with Slate Medicines, Henlius signing a US$ 322M deal with Sandoz, and KeyMed proposing a STAR Market listing. Clinical highlights feature Sunshine Guojian’s NMPA…

China Chinese drugmakers are increasingly looking past the NMPA toward approvals in the EU, US, and Australia. Daphne Smyth of Veristat has watched this shift from the front row, guiding sponsors through the data gaps, bridging studies, and regulatory quirks that stand between a China-developed drug and a Western marketing authorisation.…

Global Five conferences, five continents’ worth of anxiety, one unmistakable pattern: the global pharma industry is being reshaped faster than it can keep up. From Philadelphia to Geneva, Istanbul to Chicago to London, the Shawview Consulting team found the same threads running through every panel and corridor conversation — AI and…

Global Affordability and innovation are usually framed as a zero-sum trade-off in drug pricing debates. Zeba M. Khan, editor-in-chief of ISPOR’s Value & Outcomes Spotlight magazine, makes the case that they don’t have to be — if pricing policy is grounded in evidence rather than blunt instruments. Khan walks through the…

Africa Can a medicine be considered “available” if it can’t be trusted? As Africa’s manufacturing base expands and its regulatory systems mature, that question is moving to the centre of the continent’s health agenda. Lenias Hwenda maps out why 2026 is a turning point for African patient safety — anchored by…

USA A sustainable market for generics and biosimilars is the key to lowering the cost of medicine in the US, says John Murphy III, President and CEO of the Association for Accessible Medicines.   Following leadership changes within the FDA, actively prioritizing generic and biosimilar medicines must remain a top focus…

Europe Strong patent portfolios can create substantial commercial value for biopharma companies. As Isobel Barry, partner at life sciences-focused IP firm Carpmaels & Ransford LLP explains,  opportunities to patent new small molecule, biologics and complex therapeutics arise throughout the go-to-market process, from early-stage research, through formulation development and clinical trials, up…

Global Across the Global South, hundreds of millions of people live without reliable access to basic healthcare. Too few doctors, too little data, and systems too fragile to scale. However, as Capria Ventures’ Francis Perelman outlines, a new wave of AI-native startups is building for precisely those conditions, deploying tools that…

Germany Germany’s Medical Research Act is almost two years old. Writing in the June/July 2026 edition of DIA Global Forum, Thomas Sudhop, Claudia Riedel and Karl Broich of the Federal Institute for Drugs and Medical Devices (BfArM) outline how the Act attempts to revitalise clinical research in Germany, balancing faster procedures…

Global Sally Epstein looks at why the world’s biggest AI companies are all pivoting towards biopharmaceuticals. Epstein, an entrepreneur in residence at Cambridge Innovation Capital, argues that drug discovery – if done right – could be where the AI industry has the biggest societal impact (and can therefore justify companies’ enormous…

Global Whilst G7 countries have long been the traditional homes of pharmaceutical innovation, there is increased global competition, and a real risk that this longstanding leadership will be lost without concerted action. Ahead of the G7 Leaders’ Summit in Evian on 15-17 June 2026, David Reddy, Director General of IFPMA, stresses…

China China has built one of the world’s most advanced digital health ecosystems — large, fast-moving, and integrated across hospitals, internet platforms, insurers, pharmaceutical companies, and regulators. AI is now embedded across the entire value chain: drug discovery, clinical trial management, medical imaging, patient triage, and hospital workflows. Insilico Medicine is…